Healthcare


 Is Telix Pharmaceuticals Financially Stable in the ASX Healthcare Sector?

Is Telix Pharmaceuticals Financially Stable in the ASX Healthcare Sector?

May 16, 2025 04:32 PM AEST| By Team Kalkine Media

Is Telix Pharmaceuticals Financially Stable in the ASX Healthcare Sector?

 CSL’s 2025 Dip: What the ASX200 Healthcare Giant Signals About Long-Term Value

CSL’s 2025 Dip: What the ASX200 Healthcare Giant Signals About Long-Term Value

May 16, 2025 10:59 AM AEST| By Team Kalkine Media

Highlights,CSL’s share price sees a 15.2% decline in 2025, prompting closer scrutiny,Healthcare sector shows resilience through economic cycles,CSL’s dividend yield now exceeds its 5-year average,CSL Limited (ASX:CSL), one of Australia’s most promine...

 Could Mayne Pharma’s Takeover Evaluation Shift Sentiment on ASX Healthcare Index?

Could Mayne Pharma’s Takeover Evaluation Shift Sentiment on ASX Healthcare Index?

May 15, 2025 09:57 PM AEST| By Team Kalkine Media

Could Mayne Pharma’s Takeover Evaluation Shift Sentiment on ASX Healthcare Index?

 How Is This ASX 200 (XJO) Healthcare Stock Positioned in the Global Medical Device Market?

How Is This ASX 200 (XJO) Healthcare Stock Positioned in the Global Medical Device Market?

May 15, 2025 06:10 PM AEST| By Team Kalkine Media

How Is This ASX 200 (XJO) Healthcare Stock Positioned in the Global Medical Device Market?

 Is HiTiQ Limited (ASX:HIQ) Expanding Its Tech Reach With A Capital Raise?

Is HiTiQ Limited (ASX:HIQ) Expanding Its Tech Reach With A Capital Raise?

May 15, 2025 05:33 PM AEST| By Team Kalkine Media

Is HiTiQ Limited (ASX:HIQ) Expanding Its Tech Reach with a Capital Raise?

 Is the ASX Biotech Sector Seeing a Shift with Immutep's Lung Cancer Trial Progress?

Is the ASX Biotech Sector Seeing a Shift with Immutep's Lung Cancer Trial Progress?

May 15, 2025 04:13 PM AEST| By Team Kalkine Media

Is the ASX Biotech Sector Seeing a Shift with Immutep's Lung Cancer Trial Progress?

 Is the ASX200 Biotechnology Sector Responding to Amplia’s Clinical Progress?

Is the ASX200 Biotechnology Sector Responding to Amplia’s Clinical Progress?

May 15, 2025 02:30 PM AEST| By Team Kalkine Media

Is the ASX200 Biotechnology Sector Responding to Amplia’s Clinical Progress?

 What Are the Latest Developments in HITIQ on the ASX All Ordinaries and ASX Small Industrials Index?

What Are the Latest Developments in HITIQ on the ASX All Ordinaries and ASX Small Industrials Index?

May 15, 2025 02:25 PM AEST| By Team Kalkine Media

What Are the Latest Developments in HITIQ on the ASX All Ordinaries and ASX Small Industrials Index?

 What’s Driving IME in the Healthcare Tech Sector? Key Moves Within ASX 100

What’s Driving IME in the Healthcare Tech Sector? Key Moves Within ASX 100

May 15, 2025 02:07 PM AEST| By Team Kalkine Media

Highlights,ImExHS Limited has announced the quotation of additional fully paid ordinary securities.,The company operates in the healthcare technology sector, providing imaging software solutions.,IME is listed on the ASX with a focus on expanding liq...

 Is (ASX:MSB) Advancing In Biotech with FDA Orphan Drug Approval On ASX 300 and All Ordinaries?

Is (ASX:MSB) Advancing In Biotech with FDA Orphan Drug Approval On ASX 300 and All Ordinaries?

May 15, 2025 01:08 PM AEST| By Team Kalkine Media

Highlights:,Mesoblast,receives,FDA,orphan,drug,designation,for,Ryoncil.,The,designation,grants,marketing,exclusivity,in,the,United,States.,Applicable,to,treatment,for,acute,graft,versus,host,disease,in,children.,Mesoblast,Limited (,ASX,:,MSB,),operat...

 Is (ASX:EPN) Strengthening Capital Structure Through Loan Notes On The ASX All Ordinaries And ASX 300?

Is (ASX:EPN) Strengthening Capital Structure Through Loan Notes On The ASX All Ordinaries And ASX 300?

May 15, 2025 12:45 PM AEST| By Team Kalkine Media

Is (ASX:EPN) Strengthening Capital Structure Through Loan Notes on the ASX All Ordinaries and ASX 300?

 Why Is Mesoblast’s FDA Approval Gaining Attention on the ASX200 and NASDAQ?

Why Is Mesoblast’s FDA Approval Gaining Attention on the ASX200 and NASDAQ?

May 15, 2025 11:30 AM AEST| By Team Kalkine Media

Why Is Mesoblast’s FDA Approval Gaining Attention on the ASX200 and NASDAQ?

 ASX300: Mayne Pharma Addresses FDA Concerns Over Drug Communication

ASX300: Mayne Pharma Addresses FDA Concerns Over Drug Communication

May 14, 2025 05:32 PM AEST| By Team Kalkine Media

Highlights,Mayne Pharma clarifies recent FDA correspondence,Shares drop over 15% following trading pause,FDA letter does not impact product distribution in the US,Mayne Pharma (ASX:MYX), a healthcare company listed on the Australian Securities Exchan...

 Anteris Technologies (ASX:AVR) Q1 2025 Results: A Strategic Push in the ASX300 Space

Anteris Technologies (ASX:AVR) Q1 2025 Results: A Strategic Push in the ASX300 Space

May 14, 2025 04:32 PM AEST| By Team Kalkine Media

Highlights,Net sales decline while R&D investment surges,Strategic use of IPO funds supports pivotal clinical trial,Focus on scaling production for DurAVR® THV system,Anteris Technologies Global Corp. (ASX:AVR), a med-tech innovator now part of the b...

 Lumos Diagnostics (ASX:LDX) Hits New Milestone with Largest FebriDx Order, Eyes Stronger ASX300 Performance

Lumos Diagnostics (ASX:LDX) Hits New Milestone with Largest FebriDx Order, Eyes Stronger ASX300 Performance

May 14, 2025 04:14 PM AEST| By Team Kalkine Media

Highlights,Lumos Diagnostics receives record FebriDx order,US$126,000 deal highlights growing US demand,FebriDx adoption rises after FDA clearance,Lumos Diagnostics (ASX:LDX), a key player in rapid diagnostic solutions, has announced a significant de...

 Mayne Pharma Faces FDA Challenge Over Contraceptive Claims; Spotlight on ASX300 Healthcare Stock

Mayne Pharma Faces FDA Challenge Over Contraceptive Claims; Spotlight on ASX300 Healthcare Stock

May 14, 2025 04:07 PM AEST| By Team Kalkine Media

Highlights,Mayne Pharma withdraws presentation following FDA concerns,Company clarifies stance on product claims amid regulatory scrutiny,Shares react sharply, entering trading pause on ASX,Mayne Pharma Group (ASX:MYX), a pharmaceutical company liste...

 Austco Healthcare Expands North American Reach with $2.1M Toronto Hospital Deal | Strong Play Among ASX300

Austco Healthcare Expands North American Reach with $2.1M Toronto Hospital Deal | Strong Play Among ASX300

May 14, 2025 03:53 PM AEST| By Team Kalkine Media

Highlights,Austco Healthcare (AHC) wins $2.1M tech contract in Canada,Strategic growth push in North America gains traction,Project supports long-term value amid rising ASX dividend stocks interest,Austco Healthcare (ASX:AHC) has further strengthened...

 ASX300 Watch: Mayne Pharma Faces FDA Scrutiny Ahead of $663 Million US Deal

ASX300 Watch: Mayne Pharma Faces FDA Scrutiny Ahead of $663 Million US Deal

May 14, 2025 03:32 PM AEST| By Team Kalkine Media

Highlights,Mayne Pharma enters trading pause after FDA communication,12.2% share price drop triggers immediate halt,Regulatory concerns impact timing of upcoming acquisition,Shares of Australian pharmaceutical company Mayne Pharma (ASX:MYX) were plac...

 ASX300 Spotlight: Mayne Pharma (ASX:MYX) Faces Trading Halt Amid FDA Review

ASX300 Spotlight: Mayne Pharma (ASX:MYX) Faces Trading Halt Amid FDA Review

May 14, 2025 03:10 PM AEST| By Team Kalkine Media

Highlights,Mayne Pharma (MYX) shares paused after sharp intraday drop,U.S. FDA questions product claims,regarding,contraceptive pill,Regulatory deadline looms for official company response,Mayne Pharma Group Limited (ASX:MYX), a pharmaceutical compan...

 Anteris Technologies Scales Up for Pivotal PARADIGM Trial, Marking Big Steps in ASX200 Healthcare

Anteris Technologies Scales Up for Pivotal PARADIGM Trial, Marking Big Steps in ASX200 Healthcare

May 14, 2025 11:38 AM AEST| By Team Kalkine Media

Highlights,Over 100 patients treated with,DurAVR,® in major clinical milestone,R&D investment ramps up for global PARADIGM Trial,Expanded manufacturing and regulatory progress highlight Q1 momentum,Australian medtech innovator Anteris Technologies (A...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.